Rhumbline Advisers Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Rhumbline Advisers increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 13.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 597,467 shares of the company's stock after purchasing an additional 72,464 shares during the period. Rhumbline Advisers owned approximately 0.15% of Moderna worth $16,938,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc purchased a new stake in Moderna during the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC increased its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after buying an additional 664 shares during the last quarter. Crowley Wealth Management Inc. purchased a new stake in Moderna during the fourth quarter valued at approximately $41,000. Finally, Itau Unibanco Holding S.A. increased its holdings in Moderna by 51.2% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after buying an additional 343 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $27.46 on Friday. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $152.28. The business has a 50 day simple moving average of $26.11 and a two-hundred day simple moving average of $33.50. The firm has a market capitalization of $10.62 billion, a PE ratio of -2.96 and a beta of 1.86.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same quarter in the previous year, the firm posted ($3.07) earnings per share. The company's revenue was down 35.3% on a year-over-year basis. Equities research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MRNA shares. Evercore ISI cut their price target on Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. William Blair reissued a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. UBS Group decreased their price target on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Citigroup initiated coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a report on Thursday, May 22nd. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Moderna has an average rating of "Hold" and an average target price of $53.58.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.